Foamix Pharmaceuticals, a specialty pharmaceutical company based in Israel, announced a long term contract manufacturing and supply agreement with ASM Aerosol-Service, a liquid and semi-liquid product contract manufacturer in Switzerland, for ASM’s AMZEEQ (minocycline), a topical foam for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients, and FMX103 (minocycline), a topical foam for treatment of moderate to severe papulopustular rosacea in adults.
Through the agreement, Foamix will have access to $20 million of financing under its existing credit agreement with Perceptive and OrbiMed to fund the commercial launches of AMZEEQ and, pending FDA approval, FMX103, according to a press release.
This agreement represents another milestone in our overall strategy to bring AMZEEQ to market in January 2020 and to commercialize FMX103 when and if approved by [FDA], said David Domzalski, CEO of Foamix, in the press release. Entering into a manufacturing contract with ASM is a critical step in securing our supply chain, which we believe will ensure the availability of supply once we launch AMZEEQ and, if approved, FMX103.
